We conducted a territory-wide, multicenter, age-and prostate-specific antigen-matched cohort study comparing chemohormonal therapy and hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostate cancer. Our study showed that the use of chemohormonal therapy could prevent prostate-specific antigen progression and the development of castration resistance when compared with hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostatic cancer. Background: There is a lack of real-world data regarding the treatment outcomes of chemohormonal therapy versus hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostate cancer. Patients and Methods: We conducted a territory-wide, multicenter, age-and prostate-specific antigen (PSA)-matched cohort study comparing chemohormonal therapy and hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostate cancer. Patient and disease characteristics were reviewed. The primary outcome was PSA progression-free survival. Secondary outcomes included clinical progression-free survival and castration resistance-free survival. Kaplan-Meier and multivariate Cox regression analyses were performed. Results: From January 2015 to July 2016, 32 Chinese men with metastatic hormone-sensitive prostate cancer were treated with chemohormonal therapy, and they were matched to 32 Chinese men who were treated with hormonal therapy alone. Patient and disease characteristics were similar between the 2 groups. The chemohormonal therapy group had a significantly better PSA progression-free survival (P ¼ .001) and castration resistancefree survival (P ¼ .002) than the hormonal therapy group. There was no significant difference in the clinical progression-free survival between the 2 groups. Upon multivariate Cox regression analyses, the use of chemohormonal therapy was significantly associated with a longer time to PSA progression (hazard ratio, 0.31; 95% confidence interval, 0.31-0.73; P ¼ .008) and a longer time to castration resistance (hazard ratio, 0.38; 95% confidence interval, 0.17-0.83; P ¼ .015), but was not associated with clinical progression. Conclusions: The use of chemohormonal therapy could prevent PSA progression Clinical Genitourinary Cancer February 2019 -e203 and the development of castration resistance when compared with hormonal therapy alone in Chinese men with metastatic hormone-sensitive prostatic cancer.
Introduction
Androgen deprivation therapy has been the mainstay of treatment in metastatic prostate cancer. 1 In the past 2 decades, there have been great advances in the management of castration-resistant prostate cancer, and they include the use of androgen synthesis inhibitor, second generation anti-androgen therapy, immunotherapy, radiopharmaceutical therapy, and chemotherapy. 2 4, 5 showed that the use of chemohormonal therapy could prolong survival by 10 to 13.6 months. The differences in the results are likely to be accounted by the differences in case mix, and this highlights the importance of appropriate patient selection for chemohormonal therapy. Whether the potential survival benefits of chemohormonal therapy could be translated readily in real-life settings remain unknown. Therefore, we conducted a territory-wide, multicenter, matched cohort study to compare chemohormonal therapy and hormonal therapy alone in treating metastatic hormone-sensitive prostate cancer.
Patients and Methods
This is a territory-wide, multicenter, age-and prostate-specific antigen (PSA)-matched cohort study comparing between chemohormonal therapy and hormonal therapy alone in treating Chinese men with metastatic hormone-sensitive prostate cancer. The study was approved by our Institutional Review Board (Joint Chinese University of Hong Kong e New Territories East Cluster Clinical Research Ethics Committee/Ref. no: CRE-2017.396). All Chinese men with metastatic hormone-sensitive prostate cancer who were treated with chemohormonal therapy in all oncology units within the Hospital Authority in Hong Kong were included. They were then matched with age and PSA using a historical cohort of Chinese men with metastatic hormone-sensitive prostate cancer who were treated with hormonal therapy alone from 2000 to 2014. The bestmatched cases were selected in a 1:1 ratio.
Patient characteristics, including age, diabetes mellitus, hypertension, and dyslipidemia, were reviewed. Disease characteristics including pre-treatment PSA level, Gleason score, presence of bone metastasis, presence of visceral metastasis, and extent of disease (as defined in the CHAARTED study) were reviewed. For the comparison of the baseline characteristics, the independent sample t test was used for parametric continuous variables, the Mann-Whitney U test was used for non-parameteric continuous variables, and the c 2 test was used for categorical variables. The primary outcome was PSA progression-free survival. Based on the Prostate Cancer Working Group 2 definition, PSA progression was defined as an increase of ! 25% and ! 2 ng/mL 12 weeks after the initial treatment. 6 The mean age was 64.6 AE 4.9 years in the chemohormonal therapy group and 65.5 AE 5.7 years in the hormonal therapy alone group. The mean pre-treatment PSA was 1195.5 AE 1567.5 ng/mL in the chemohormonal therapy group and 1487.0 AE 2530.1 ng/mL in the hormonal therapy group. The majority of the patients had a high Gleason score of 8 to 10 in both the chemohormonal therapy group (85.7%) and the hormonal therapy group (80.8%). Most (> 90%) patients had bone metastases in both the chemohormonal therapy group and the hormonal therapy group. Visceral metastasis was present in 12.5% of the chemohormonal therapy group and 9.4% of the hormonal therapy group. The vast majority of the patients had high-volume disease in both the chemohormonal therapy group (96.9%) and the hormonal therapy group (93.8%). There were no significant differences in the baseline patients' and disease characteristics between the 2 groups (Table 1) .
Upon Kaplan-Meier analysis, the chemohormonal therapy group had a longer PSA progression-free survival than the hormonal therapy group (P ¼ .001) ( Figure 1 ). The median PSA
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Chemohormonal Therapy Vs Hormonal Therapy in Chinese mHSPC progression-free survival was 20.5 months in the chemohormonal therapy group and 8 months in the hormonal therapy group. There was no significant difference in the clinical progression-free survival between the 2 groups ( Figure 2 ). The chemohormonal group had a longer time to castration resistance-free survival than the hormonal group (P ¼ .002) (Figure 3 ). The median castration resistance-free survival was 17.6 months in the chemohormonal therapy group and 8 months in the hormonal therapy group.
Upon multivariate Cox regression analyses (Table 2) , the use of chemohormonal therapy was significantly associated with a longer time to PSA progression (hazard ratio, 0.31; 95% confidence interval, 0.31-0.73; P ¼ .008). No other factors were associated with PSA progression. The use of chemohormonal therapy was not associated with clinical progression; neither were other patient or disease factors. The use of chemohormonal therapy was significantly associated with a longer time to castration resistance (hazard ratio, 0.38; 95% confidence interval, 0.17-0.83; P ¼ .015). No other 
Discussion
Androgen deprivation therapy was first reported by Huggins et al more than 75 years ago, 1 and it has been shown to reduce cancer-related morbidities, including bone pain, pathologic fracture, spinal cord compression, and extra-skeletal metastases. 10 Since then, the use of hormonal therapy has become the cornerstone treatment of advanced prostate cancer. However, the majority of patients with prostate cancer would develop castration resistance after 2 to 3 years of hormonal treatment, 11, 12 and this has led to extensive research work on secondary hormonal manipulation [13] [14] [15] and the use of other agents, Docetaxel had been shown to prolong overall survival in patients with metastatic hormone-refractory prostate cancer. 16, 17 However, the survival benefit of chemotherapy of 1.9 to 2.4 months at this rather advanced disease stage was only modest. Subsequently, 3 RCTs, namely the GETUG-AFU 15 study, 3 the CHAARTED study, 4 and the STAMPEDE study, 5 had been conducted to investigate the use of chemohormonal therapy in metastatic hormonesensitive prostate cancer. The GETUG-AFU 15 trial was a multicenter study conducted in Europe involving 385 patients. 3 This was the first RCT comparing chemohormonal therapy and hormonal therapy in treating metastatic hormone-sensitive prostate cancer; however, no significant difference in overall survival was detected between the 2 groups. The authors concluded that chemotherapy should not be used as part of the first-line treatment for patients with metastatic hormone-sensitive prostate cancer. The CHAARTED study was a multicenter study conducted in the United States involving 790 patients. 4 This study was able to demonstrate a significant overall survival benefit of 13.6 months in patients with metastatic hormone-sensitive prostate cancer. Upon subgroup analysis, it was found that the survival benefit was most remarkable in patients with high-volume disease, in which high-volume disease was defined as the presence of visceral metastases or ! 4 bone lesions with ! 1 beyond the vertebral bodies and pelvis. The STAMPEDE was a multi-arm, multi-stage study conducted in the United Kingdom. 5 The research group reported results from 4 treatment arms (standard of care only, standard of care plus zoledronic acid, standard of care plus docetaxel, and standard of care plus zoledronic acid and docetaxel) including a total of 3983 patients. Patients with high-risk locally advanced disease, node-positive disease, and metastatic hormone-sensitive disease, as well as those with relapsing disease following radical surgery and/or radiotherapy with high-risk features, were included. The results showed that the addition of docetaxel was able to prolong overall survival by 10 months. Such survival benefit was detected in patients with metastatic disease, but not those with non-metastatic disease upon subgroup analysis. In summary, 2 RCTs showed positive results, and 1 RCT showed negative results. The differences in case mix are likely to explain the conflicting results. This highlights the importance of case selection, and whether the survival benefit of chemohormonal therapy could be replicated in the real-life setting is an important issue to be explored. Therefore, we decided to conduct a territory-wide, multicenter cohort study comparing chemohormonal therapy and hormonal therapy in patients with metastatic hormone-sensitive prostate cancer. As chemohormonal therapy is usually indicated in younger patients and seems to be more efficacious in patients with more advanced disease, we decided to match the 2 groups according to their ages and PSA levels. As the staging imaging modalities were not standardized in our cohort, we did not use the extent of disease for the matching process; PSA level was used instead as it is proportional to the volume of disease in most of the cases. Nevertheless, the vast majority of the patients had high-volume disease in both groups, and there was no significant difference between them. Other baseline patient and disease characteristics were also confirmed to be balanced between the 2 groups. In Hong Kong, we have been using chemohormonal therapy to treat metastatic hormonesensitive prostate cancer since January 2015; with a relatively short follow-up, we decided to use PSA progression-free survival as the primary outcome of this study. Nevertheless, PSA progression has long been used as a surrogate marker for overall survival, and we believe it can still provide valuable information regarding our subject of interest. 7 We have also included clinical progression-free survival and castration resistance-free survival as our secondary outcomes, which are equally important in managing patients with metastatic hormone-sensitive prostate cancer. Our results showed that the chemohormonal therapy group had a better PSA progression-free survival and castration resistance-free survival than the hormonal therapy group. Such associations were confirmed upon multivariate analyses after adjusting for other potential confounding factors. The majority of the patients who developed castration resistance had PSA progression rather than clinical progression. Therefore, we did not detect any significance difference in the clinical progression-free survival between the 2 groups. This might also be explained by the relatively short follow-up period of our patients. The 1-year overall survival rate was 100% for the chemohormonal group and 72% in the hormonal group. However, owing to the relatively short follow-up period in the chemohormonal group, we did not perform further survival analysis. Nevertheless, based on the differences in PSA progression-free survival and castration resistancefree survival, we believe that the use of chemohormonal therapy was able to benefit our Chinese patients with metastatic hormone-sensitive prostate cancer in the real-life setting. There are several limitations in our study. First, it is a retrospective study, and there is no standardized follow-up protocol. We regularly monitored the PSA level upon follow-up, but imaging was only performed when clinically indicated, and the results on clinical progression might therefore be inaccurate. Second, because it is a non-randomized study, there might be bias in terms of patient selection. However, we have tried to minimize this bias by matching, and the baseline patient and disease characteristics were balanced between the 2 groups. Third, the sample size of our study is small. However, it is already a territorywide study involving all oncology centers within the Hospital Authority in Hong Kong. We believe the results could provide valuable information regarding the use of chemohormonal therapy in our locality. Fourth, our follow-up period is relatively short to provide information regarding overall survival. However, we believe PSA progression-free survival could serve as surrogate marker in our cohort, and we shall update our results on overall survival in the future.
In Hong Kong, we witnessed a gradual change in the treatment paradigm from conventional hormonal therapy to chemohormonal therapy in metastatic hormone-sensitive prostate cancer. As evidence emerges, the initial concern about the benefit and toxicities of chemotherapy gradually becomes more acceptable to urologists and oncologists. The results from this territory-wide study are promising, and we hope to provide more information on the long-term survival outcomes in the near future.
Conclusions
Our study demonstrated that the use of chemohormonal therapy could prevent PSA progression and the development of castration resistance when compared with hormonal therapy-alone in Chinese men with metastatic hormone-sensitive prostatic cancer. Long-term survival outcomes are to be awaited.
Clinical Practice Points
There were 3 RCTs investigating the use of docetaxel in addition to hormonal therapy in managing patients with metastatic hormonesensitive prostate cancer, but the results were conflicting. The differences in the results are likely to be accounted by the differences in case mix, and this highlights the importance of appropriate patient selection for chemohormonal therapy. Whether the potential survival benefits of chemohormonal therapy could be translated readily to real-life settings remain unknown. Therefore, we conducted a territory-wide, multicenter, matched cohort study to compare chemohormonal therapy and hormonal therapy alone in treating metastatic hormone-sensitive prostate cancer.
Our study showed that the chemohormonal therapy group had a significantly better PSA progression-free survival and castration resistance-free survival than the hormonal therapy group. There was no significant difference in the clinical progression-free survival between the 2 groups. Upon multivariate Cox regression analyses, the use of chemohormonal therapy was significantly associated with a longer time to PSA progression and a longer time to castration resistance, but not associated with clinical progression. The side effects of chemohormonal therapy in Chinese men were, in general, tolerable. Although the preliminary results are promising, long-term survival outcomes are to be awaited.
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